The API industry has entered the 3.0 era,it is neccessary to shift from traditional APIs to high-barrier specialty APIs,patented APIs, and biopharmaceutical raw materials.

By overcoming more complex synthesis processes and meeting stricter regulatory standards, we aim to integrate into the global high-value pharmaceutical industry chain. This represents a crucial leap from “cost competition” 宛先 “competition based on technology and quality”.

Our GMP projects for specific API will be carried out according to market and customers’ demand to cater to the 3.0 era.